收入3亿！增长14.56%！安杰思最新半年报

Core Viewpoint - The company, Anjisi, reported a revenue increase of 14.56% in the first half of 2025, indicating strong growth in both domestic and international markets [3][6]. Financial Data - The total revenue for the first half of 2025 was approximately 302.43 million RMB, compared to 264.00 million RMB in the same period last year, reflecting a growth of 14.56% [3]. - The total profit for the period was 149.13 million RMB, a slight increase of 2.78% from 145.10 million RMB year-on-year [3]. - The net profit attributable to shareholders was 126.02 million RMB, showing a year-on-year increase of 1.26% [3]. - The net profit after deducting non-recurring gains and losses was 111.51 million RMB, which represents a decline of 7.06% compared to the previous year [3][4]. - The net cash flow from operating activities was 75.69 million RMB, down 34.90% from 116.27 million RMB in the same period last year [4]. Market Performance - Domestic market sales revenue was approximately 137 million RMB, reflecting a growth of 10.07% year-on-year [6]. - International market sales revenue reached about 163 million RMB, marking an 18.29% increase compared to the previous year [6]. Research and Development - The company invested 34.46 million RMB in research and development, which is a 33.29% increase year-on-year [4]. - Anjisi has applied for a total of 421 patents, including 270 invention patents, 127 utility model patents, and 24 design patents, with 102 patents granted [6][9]. Company Overview - Anjisi Medical Technology Co., Ltd. specializes in the research, development, production, and sales of minimally invasive diagnostic and therapeutic instruments, established in December 2010 and successfully listed in May 2023 [7]. - The company's product range includes hemostatic closure devices, EMR/ESD devices, biopsy tools, ERCP devices, and various instruments, widely used in five major fields: digestive endoscopy, respiratory endoscopy, ENT endoscopy, urological endoscopy, and gynecological endoscopy [7].